Background/Aims: Hepatocyte transplantation and bioartificial liver treatment are attractive alternatives to liver transplantation. The availability of well-characterized human hepatocyte lines facilitates such cell therapies.
Introduction
Acute liver failure (ALF), which affects approximately 2000 persons per year in the United States, is characterized by severe and sudden liver cell dysfunction that results in coagulopathy and hepatic encephalopathy in previously healthy individuals [1] . This catastrophic illness can rapidly progress to coma and death from cerebral edema and multiorgan dysfunction. Although orthotopic liver transplantation (OLT) remains the only curative therapy for patients with acute or terminal liver failure, this procedure is highly costly, complex, and limited by the scarcity of donor livers [2] . Since Berry and Friend established a method to isolate hepatocytes from whole livers in 1969 [3] , laboratory animal studies and limited clinical trials have demonstrated that hepatocyte transplantation (HT) can potentially be used for the treatment of liver failure [4] [5] [6] and inborn errors of liver metabolism [7, 8] . HT presents distinct advantages over OLT for organ replacement therapy: (i) HT is technically simpler than OLT, requiring only intraportal injection of a cell suspension, (ii) hepatocytes can be cryopreserved for future use and (iii) hepatocytes obtained from one donor can be used for multiple patients [4, 9] . Yet, major obstacles to the broad clinical use of HT include the competition with OLT for the few suitable donor livers and the fact that primary hepatocytes cannot be readily expanded in vitro [4, 9] .
To address these issues, we have previously shown that primary human hepatocytes can be expanded in vitro through a procedure of ''reversible immortalization'' by retrovirus-mediated transfer of an immortalizing oncogene (simian virus 40 large T antigen (SV40 T)) that can be subsequently excised by Cre/Lox-mediated site-specific recombination [10, 11] . Reverted hepatocytes were capable of protecting partially hepatectomized rats from acute liver failure after intrasplenic transplantation [11] , and this procedure was then extended by us and others to various cell types [12] [13] [14] [15] . However, the requirement for expression of the Cre recombinase at the completion of the expansion phase in order to trigger irreversible excision of the integrated oncogene necessitated secondary virus-mediated gene transfer in a large number of cells. This technical requirement has presented a formidable hurdle to make this approach practical for human patients, and proof-of-principle in a large animal was lacking.
Here, we have extensively modified this approach by utilizing human telomerase reverse transcriptase (hTERT) as the immortalizing cDNA and making it self-excising in the presence of Tamoxifen without the need for secondary gene transfer. Unlimited supplies of reverted human hepatocytes were obtained, thus allowing large-scale production and the first demonstration of efficacy in a large animal model of ALF.
Materials and methods

Hepatocyte immortalization and culture
A polycistronic retroviral vector, SSR#197, was constructed as described previously [15] . Human hepatocytes were purchased from Cell systems Co. (Seattle, WA) and cultured with chemically defined serum-free CS-C medium (Cell systems Co.). Hepatocytes (1 · 10 6 ) were transduced with 2 mL of wCrip SSR#197-producing cell supernatant in the presence of 12 mg/ml polybrene (Sigma) at 37°C for 4 h two times a day for 3 days. Two days after the final transduction, cells were subjected to flow cytometric cell sorting for recovering GFP-positive populations, as previously described [15] . These GFP-expressing cells were cloned in 96 well plates using a limiting dilution method. Based on the gene expression profile assessed by RT-PCR, as described below, and lack of tumorigenicity (Table 1) , one of 24 clones, clone no.16, was selected for subsequent transfection.
Integration of the Tamoxifen-dependent Cre recombinase-expression cassette (MerCreMer)
Clone no. 16 was transfected by means of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) with the plasmid pCAGMerCreMer/Puro that expresses a Cre recombinase protein fused to two mutant estrogen-receptor ligand-binding domains (MerCreMer) under the control of the CAG promoter (kindly provided by Michael Reth, MPI fur Immunobiologie, Freiburg, Germany), which is a composite of the Cytomegalovirus IE enhancer and the chicken b-actin promoter [16] . Seventy-two hours after transfection, selection with 5 lg/ml puromycin was initiated. Within 4 weeks, puromycin-resistant colonies emerged and a total of 40 clones were isolated using cloning rings. On the basis of Cre/LoxP recombination efficiency, cell line 16-T3 was selected for further study and was maintained in serum-free ISE-RPMI [17] medium containing 3 lg/ml puromycin.
Tamoxifen-mediated Cre/LoxP recombination
16-T3 cells were inoculated in T175-flasks, and 500 nM 4-hydroxytamoxifen (4-HT) (Sigma, Saint Louis, MI) was added 24 h later to the ISE-RPMI culture medium. The cells were maintained in the presence of 4-HT for a week and then subjected to flow cytometric analysis with a Moflo sorter (DakoCytomation, Tokyo, Japan). Then, the reverted population of 16-T3 cells was recovered by EGFP-negative cell sorting and further characterized (Fig. 1). 
Telomerase activity
Telomerase activity in 16-T3 cells was assayed by the PCR-based telomeric repeat amplification protocol (TRAP) using a TRAPEZE telomerase detection kit (Serologicals, Norcross, GA) according to the manufacturer's protocol. Cellular extracts from 16-T3 cells were diluted to 100 ng/ml. Two microliters of each cellular extract was subjected to the TRAP assay before being loaded on a 10% polyacrylamide gel, and products were visualized by SYBR Green I staining (Molecular Probes, Eugene, OR) as described previously [14, 15] .
Assay for oncogenicity
To evaluate the potential tumorigenicity of immortalized or reverted 16-T3 cells, 1 · 10 7 cells were transplanted into the right shoulder or right thigh of SCID mice, respectively (KLEA Japan, Tokyo, Japan). As a positive control, 1 · 10 7 PLC/PRF/5 cells derived from a human hepatoma cell line [18] were transplanted into the left shoulder of the mice. Mice were observed for at least 6 months.
Gene expression of hepatocyte markers
Total RNA was isolated from 16-T3 or its reverted form and subjected to reverse transcription and polymerase chain reaction (RT-PCR) and Northern blot analyses with specific primers and probes, as previously described [11] . Primers used were as follows: albumin The amplification reaction involved denaturation at 95°C for 30 s, annealing at 58°C for 30 min, and 72°C for 30 min using a thermal cycler (Perkin-Elmer, Foster City, CA) at 30-35 cycles for all markers. The PCR products were resolved on 1% agarose gels and visualized by ethidium bromide staining. The intensity of the bands of liver markers to human b-actin, used as an internal control, in both immortalized and reverted cells, was comparatively presented using NIH Image.
Evaluation of hepatocyte-specific functions
Immunofluorescent staining for albumin was conducted with immortalized and reverted 16-T3 cells with a labeled anti-albumin antibody, as previously reported [19] . Staining with Oregon green phalloidin (Molecular Probes, Eugene, OR) and Hoechst dye (Sigma, Saint Louis, MI) was simultaneously performed for specific staining of actin filaments and nuclei, respectively. Ten microliters of culture medium from 1 · 10 6 immortalized and reverted 16-T3 cells cultured with ISE-RPMI medium for 24 h was subjected to albumin production analysis using the Human Albuwell II kit (Exocell Inc., Philadelphia, PA) according to the manufacturer's protocol. Immortalized, reverted, and normal human hepatocytes (1 · 10 6 cells) were inoculated in each well of a 6-well plate per 24 h per mg of cellular protein to evaluate metabolic activity of lidocaine (1 mg/mL) (Fujisawa Pharmaceutical Co., Osaka, Japan). Concentration of lidocaine was measured by SRL Co. (Okayama, Japan). Primary isolated human hepatocytes (kindly gifted by Dr. S. Suzuki at the Huamn Animal Bridge (HAB) Institute (Ichikawa, Japan) were used as a positive control. 
ALB, albumin; AGPR, asialoglycoprotein receptor; BUGT, bilirubin-UDP-glucuronosyltransferase; CYP, cytochrome P450 3A4; GS, glutamine synthetase; GST, glutathione-S-transferase-p; HBCFX, human blood coagulation factor X. The expression of these hepatic markers was assessed by RT-PCR. a Tumorigenicity was assayed using SCID mice. 
Growth curves and cell cycle analysis
Immortalized and reverted 16-T3 cells were inoculated at a density of 1 · 10 5 per well in 6-well plates and cultured in ISE-RPMI medium. The cells were regularly detached with trypsin and the number of viable cells counted by trypan blue exclusion test. The cell cycle status of both 16-T3 and reverted cells was analyzed by flow cytometry, as previously reported [19] .
Animal experiments
All procedures performed on animals were within the guidelines for humane care of laboratory animals and approved by the Okayama University Institutional Animal Care and Use Committee. Porcine hepatocytes were prepared from Landrace pigs (JA West of Okayama, Okayama, Japan), weighing 10 kg, by a four-step retrograde perfusion method using collagenase and dispase, as previously described [20] . The isolated hepatocytes with cell viability of >85% were used for transplant experiments. 16-T3 cells were expanded in a roller bottle (Falcon BD) using a cell preparation roller apparatus (Bellco Co., Tokyo, Japan), and used for the transplantation experiments. Landrace male pigs, weighing approximately 6 kg, were used as a recipient for transplantation experiment. An atom multipurpose tube (6 Fr.) (Atom Medical Co., Tokyo, Japan) was surgically inserted into a left external jugular vein for D-galactosamine (D-Gal) injection under general anesthesia. At the same time, the spleen was exposed after abdominal incision. An atom tube of 6 Fr. was inserted from a branch of the splenic vein and the tip of the tube was placed in the main portal vein via for cell transplantation. After closing the abdomen, intravenous administration of 0.5 g/kg of D-Gal (Sigma, Saint Louis, MI) was conducted via the jugular route 24 h prior to cell transplantation. Both of the tubes were flushed with 1000 U of heparin (Aventis, Tokyo, Japan) to prevent blood clotting, capped, and then subcutaneously embedded for the following transplantation experiment, as previously reported [20] . Recipient pigs were randomly divided in the following groups: G1, single intraportal injection of reverted 16-T3 cells (1 · 10 9 cells) (n = 5); G2, single intraportal injection of primary isolated pig hepatocytes (1 · 10 9 cells, which were compatible to 5% mass of the whole of the pig liver) as a positive control (n = 3); and G3, intraportal injection of Ringer's Lactate solution as a negative control (n = 5). After the transplantation procedure, pigs had free access to food and water. A daily intramuscular injection of 0.5 mg/kg of FK506 was conducted in the pigs from 1 day before cell transplantation to 7 days after transplantation. Blood samples were regularly taken from the pigs for analyzing liver functions and for measuring human specific albumin to evaluate engraftment of the reverted 16-T3 cells in pigs using a Human ALBU-WELL II ELISA kit (Exocell Inc.).
Histopathological examinations
Autopsies were performed in all pigs at the time of spontaneous death or sacrifice. The liver and spleen specimens obtained from animals subjected to cell transplant as well as D-Gal-treated animals that received medium and only Ringer's Lactate were fixed with 20% formalin embedded in paraffin and processed for staining with hematoxylin and eosin (HE). The liver biopsy specimens obtained from pigs transplanted with reverted 16-T3 cells were also cryopreserved with OCT-Tissue TECH compound (R&D Systems, Minneapolis, MN). Five lm sections were prepared for immunofluorescent staining for human specific albumin expression by means of a mouse monoclonal anti-human albumin antibody (Santa Cruz Biotech, Santa Cruz, CA) and followed by FITC-conjugated goat anti-mouse IgG (Sigma, Saint Louis, MI). Localization of albumin was visualized by an Axiophot FL fluorescence microscope (Carl Zeiss, Oberkochen, Germany).
Statistical analysis
Mean values are presented with standard deviations. A two-tailed Student's t test was used to calculate the significance of difference in mean values. The Kaplan-Meier method was used to calculate survival data and the significance of differences determined by a Logrank test. A p-value of <0.05 was considered statistically significant.
Results
Establishment of a reversibly immortalized human hepatocyte cell line 16-T3 with Tamoxifen-mediated self-recombination
Human hepatocytes were immortalized with SSR#197 that constitutively expresses LoxP-flanked hTERT and EGFP (Fig. 1) . One of 24 EGFP-positive clones, clone no. 16, was chosen on the basis of results from gene expression profiles assessed by RT-PCR and tumorigenic assays ( Table 1 ). The clone no. 16 was further subjected to transfection with the plasmid pCAGMerCreMer/Puro R , which expresses a Cre recombinase protein fused to two mutant estrogen-receptor ligand-binding domains (MerCreMer) (Fig. 1) . The MerCreMer/Puro R cDNA was placed under the control of the CAG promoter. After transfection with a plasmid conferring resistance to puromycin and subsequent selection, a resultant clone, 16-T3, was isolated for further studies on the basis of Cre/LoxP recombination efficiency. 16-T3 cells grew steadily in culture with serum-free medium and doubled in cell number in approximately 48 h.
Cre/LoxP recombination in the presence of 4-hydroxytamoxifen
The EGFP-negative population was recovered by high-speed cell sorting in 16-T3 cells after a week-exposure to 4-hydroxytamoxifen (4-HT). The cells (reverted 16-T3 cells) were uniformly negative for EGFP expression by histogram study and FITC-based phase contrast microscopy (Fig. 2a) . The cells lost expression of hTERT (Fig. 2b) analysis and telomerase activity (Fig. 2c) , resulting in loss of proliferation (Fig. 2d) . No change in the proportion of cells expressing EGFP was observed in a control experiment employing 17b-estradiol instead of 4-HT.
Reverted 16-T3 cells express differentiated hepatocyte phenotypes
Expression of hepatocyte-specific genes, including albumin (Alb), glutathione-S-transferase p (GST), and human blood coagulation factor X (HBCFX), was further increased in reverted 16-T3 after 4-HT treatment by both RT-PCR (Fig. 3a) and Northern blot analyses (Fig. 3b) . The enhanced expression after Cre/LoxP recombination was at least in part explained by increased expression of the transcriptional factors CCAAT/enhancer binding protein (C/EBP)-a and hepatocyte nuclear factor (HNF)-4a (Fig. 3b) . Increased production of albumin was also observed in reverted 16-T3 by immunofluorescent study (Figs. 3c and d) and by measuring secreted albumin into the culture medium by ELISA (Fig. 3g) . Reverted cells progressively stopped proliferating in the G0/G1 phase of the cell cycle (Figs. 3e and f). Lidocaine metabolic activity was significantly increased in reverted cells (Fig. 3h) . Compared to normal human hepatocytes, albumin production and lidocaine-metabolizing activities of reverted 16-T3 cells were 0.32 and 0.50-fold, respectively.
Transplantation of reverted cells via the portal vein ensures long-term survival of pigs with ALF
We evaluated the therapeutic effect of the reverted 16-T3 cells in a pig model of ALF induced by intravenous injection of 0.5 g/kg of D-Gal. Animals were injected with the immunosuppressant FK 506 to delay rejection of the injected cells in this xenotransplantation model until spontaneous liver regeneration occurred. While blood levels of total bilirubin (Fig. 4a) , AST (aspartate aminotransferase) (Fig. 4b) , ammonia (NH3) (Fig. 4c ) and prothrombin time (PT) (Fig. 4d ) increased up to 72 h after D-Gal injection in all animals, they gradually recovered to normal levels in the pigs with intraportal transplantation of either reverted 16-T3 cells or porcine hepatocytes. In contrast, control pigs injected with Ringer's Lactate solution showed rapid increase in these parameters and eventually died of liver failure with hemorrhage and jaundice within 4 days after D-Gal injection. Blood levels of tumor necrosis factor (TNF)-a were considerably higher in control pigs, whereas pigs transplanted with either reverted 16-T3 or porcine hepatocytes had almost normal values of TNF-a (Fig. 4e) . However, G1 and G2 pigs transiently showed the higher blood level of ALP (alkaline phosphatase) for a couple of days after cell transplantation than control pigs due to cell injection in the portal vein (Fig. 4f) .
Survival and histological findings
The one-month survival rate was 100% for pigs transplanted with porcine hepatocytes and 80% for pigs with reverted 16-T3 transplant, respectively, whereas none of the vehicle-injected pigs survived (Fig. 5a ). The status of engraftment of transplanted reverted 16-T3 cells was evaluated by measuring the blood level of human specific albumin in the pigs. Under FK506 administration, reverted 16-T3 cells survived in the liver of pigs for at least 4 days that were a crucial period of time to support the damaged liver to regenerate (Fig. 5b) . These data suggest that the transplanted reverted 16-T3 cells degraded inflammatory cytokines, such as TNF-a, effec- tively and supported hepatic functions until pigs recovered from ALF. Liver biopsy samples obtained on day 3 post-transplantation with reverted 16-T3 cells showed clusters of human cells that were positive for human specific albumin expression in the portal areas, accompanied with severe necrosis of the liver (Figs. 5c and  d) . Liver specimens taken 15 days after D-Gal injection in the 16-T3 cell transplanted group revealed almost normal hepatic trabecular architecture with moderate mononuclear infiltrate, indicating complete recovery from ALF and host rejection of the transplanted cells (Figs. 5e and f) . At the time of sacrifice 3 months post-transplantation, there was no evidence of tumor development in liver, lung, bone marrow and other organs of the pigs injected with the reverted 16-T3 cells.
Discussion
In many cases of ALF, the damaged liver would spontaneously regenerate if bridging life-support could be provided by transient transplantation of functional hepatocytes [4] . In an effort to provide a practical source of cells for this therapy despite the shortage in liver donors, we previously developed a reversible cell immortalization procedure by retroviral transfer of a viral oncogene of SV40 that could be subsequently excised by Adenovirus-mediated Cre/LoxP site-specific recombination [10, 11] . However, three major hurdles remained to obtain a sufficient number of reverted cells for clinical applications. First, SV40 T-mediated cell expansion was unable to avoid replicative cell senescence at the time of excision of the oncogene, because telomere attrition was not prevented, thus limiting the number of viable cells that could be obtained. Second, oncogenic concerns remained with the use of the viral oncogene SV40 T. Lastly, adenovirus-associated cytotoxicity induced considerable cell loss, and possible lingering contamination by adenoviral structural proteins could not be ruled out.
In this study, we have use two prolonged approaches to surmount these hurdles. First, hTERT was used as the immortalizing protein, thus preserving telomere length and avoiding the use of a viral oncogene [21] . Second, we pre-integrated in the immortalized hepatocyte clone a DNA construct that expresses a Tamoxifendependent Cre recombinase fusion protein, thereby making secondary virus-mediated transfer of the recombinase gene unnecessary.
After removal of hTERT in immortalized 16-T3 cells by adding Tamoxifen, the reverted 16-T3 cells progressively arrested in the G0/G1 phase of the cell cycle. Loss of proliferating capacity in immortalized cells may allow the cells to use the energy for expressing the more differentiated phenotypes. In fact, the reverted 16-T3 cells showed the increased expression of hepatic markers in association with enhanced levels of transcriptional factors C/EBP-a and HNF-4a, resulting in higher albumin production and lidocaine metabolism (Figs. 3a and b) . Furthermore, transplantation of reverted 16-T3 cells successfully prevented the elevation of the blood level of inflammatory cytokine TNF-a in the pigs with ALF induced by D-Gal, leading to the significant prolongation of the survival. In our current bioartificial liver (BAL) experiments, D-Gal-induced ALF pigs showed decrease in the blood TNF-a level after BAL therapy and survived. In contrast, control pigs revealed the higher level of TNF-a and died within 4 days of D-Gal injection (data not shown).
Complementary measures to enable the rapid clinical isolation of reverted cells while avoiding the need for EGFP-mediated cell sorting could be further developed, such as by means of a membrane marker recognized by biodegradable, magnetic immunolabeled nanoparticles for rapid, single-batch cell purification [22] . Other means of triggering excision of the immortalizing gene without the need for gene transfer could also be explored, such as the use of a TAT-Cre recombinase fusion protein capable of penetrating cell membranes [23] .
Results from the porcine xenotransplantation model suggest that non-histocompatible allogenic transplantation in the presence of FK506 would be effective to bridge patients with ALF until their liver spontaneously regenerates and transplanted cells are ultimately rejected. Repeated intraportal administration of reverted hepatocytes is available by means of a PORT-A CATH catheter inserted from the middle portion of the splenic vein with the tip positioned inside the portal vein and the site of cell infusion subcutaneously embedded into the groin region [24] . In this setting, the use of non-histocompatible cells is a powerful added security against any potential tumorigenicity.
This approach may also be extended to the long-term cell therapy of terminal, chronic liver diseases and liver inborn errors of metabolism. HLA-matched liver cells could be obtained by limited liver biopsy of related individuals and submitted to the procedure of reversible immortalization. In the case of terminal, chronic liver disease, the donor cells could be further modified by gene correction by additional gene transfer. For instance, expression of a dominant negative mutant or ) as a positive control (n = 3); and G3, intraportal injection of 100 ml Ringer's Lactate solution as a negative control (n = 5). Control G3 pigs experienced a rapid increase in blood total bilirubin levels (T. Bil) (a) and ammonia (NH3) (c) with marked decrease in prothrombin time (PT) (d). In contrast, these parameters as well as AST (b) and ALP (f) returned to normal levels 72 h after D-Gal injection in G1 pigs and G2 pigs. Pigs with cell transplant (G1 and G2) showed the higher ALP level due to intraportal cell infusion (f). Blood levels of TNF-a were considerably elevated in control G3 pigs, whereas G1 and G2 pigs demonstrated almost normal levels of TNF-a after D-Gal administration (e). Data are averages ± SD of repeated samples from individual animals. 16-T3 cells were used for the transplantation experiments.
an siRNA may be effective at rendering the cells resistant to Hepatitis C replication [25] . In the case of liver inborn errors of direct metabolism, autologous hepatocytes could be obtained by limited liver biopsy. Subsequent gene transfer in autologous hepatocytes submitted to the reversible immortalization procedure could allow long-term correction of a genetic disease such as the hemophilias or hypercholesterolemia caused by deficiency in the low density lipoprotein receptor. A potential advantage of this approach as compared to direct in vivo gene therapy is that expression of the therapeutic gene will be restricted to hepatocytes without the risk of triggering a cytotoxic immune response by inadvertant in vivo transduction of antigen presenting cells residing in the liver [26] . In addition, direct gene correction by homologous recombination or gene repair would now be attainable in the immortalized cell population. In clinical situations where the cells are not expected to be rejected by a mismatched host immune system (i.e., autologous and allocompatible cell transplantation), a conditional suicide gene such as Herpes Simplex Virus-thymidine kinase (HSV-TK) could be constitutively expressed in the cells for additional safety [27] .
In conclusion, Cre/LoxP-mediated reversible immortalization of human hepatocytes with Tamoxifen-mediated self-recombination made unlimited supplies of reverted cells feasible, allowing a proof-of-principle demonstration of their utility in a pig model of ALF.
